← Back to Home

Tailoring Vaccines to Tumors: Phase 3 Trial Reduces Risk of Recurrence or Death After Melanoma Surgery

A trial involving more than 1,000 people shows that a personalized mRNA vaccine combined with immunotherapy can further improve outcomes after surgery for patients with high-risk melanoma; whether it can extend overall survival will take longer to determine.

By SURL BioNews

Surgery removes visible tumors, but it may not eliminate every cancer cell. For melanoma patients at higher risk of recurrence, treatment after surgery aims to close that gap. A phase 3 clinical trial involving 1,137 people now shows that adding an mRNA vaccine tailored to the characteristics of each patient’s tumor to existing immunotherapy can further reduce the risk of recurrence or death.

The global randomized, double-blind trial, called INTerpath-001, enrolled patients with stage IIB to IV melanoma whose tumors had been completely removed. About two-thirds received the personalized vaccine intismeran autogene (also known as V940 or mRNA-4157) combined with pembrolizumab, while the rest received a placebo combined with pembrolizumab. The results were presented at the European Society for Medical Oncology annual meeting in October 2026. The trial was funded by Merck and Moderna.

According to the prespecified primary analysis released by Moderna, after a median follow-up of 24.6 months, the combination treatment group had a 42% lower risk of recurrence or death than the control group, with a hazard ratio of 0.58 (95% confidence interval, 0.45 to 0.75; p<0.001). Information from Memorial Sloan Kettering Cancer Center indicated that, at approximately two years, recurrence-free survival exceeded 82% in the combination treatment group, compared with about 70% in the control group. This puts the relative risk reduction into more concrete terms: 42% does not mean a 42-percentage-point increase in survival, nor can it be directly interpreted as a 42% reduction in the risk of death alone.

The vaccine’s design starts with the differences in each patient’s cancer cells. Researchers analyze tumor and blood samples to identify mutations unique to the tumor, then use computational methods to select up to 34 “neoantigens” expected to be recognized by the immune system and encode them in mRNA. The aim is to guide immune cells to recognize cancer cells that may remain; pembrolizumab, given alongside the vaccine, blocks PD-1 inhibitory signaling, reducing the restraints on T cells. This is a vaccine for cancer treatment, intended for use after a patient has developed cancer and undergone tumor removal.

Beyond efficacy, both groups still faced treatment burdens. Moderna reported that grade 3 to 5 treatment-related adverse events occurred in 14.2% of the combination treatment group and 13.4% of the control group, with no new safety signals observed. Common vaccine-related side effects listed by the cancer center included fever, injection-site pain, and fatigue. These data help assess the burden of adding the vaccine, but the current follow-up cannot yet capture all long-term risks.

Personalized therapy also faces a practical test: a separate product must be made for each patient. Moderna said manufacturing was successfully completed for more than 99% of patients randomized to receive the vaccine in the trial. This supports the feasibility of making vaccines for individual patients in a large multinational trial. Whether they can be supplied in routine care at an affordable cost and within an appropriate timeframe remains unanswered by the information available.

The clearest advance so far is that this combination improved recurrence-free survival in a specific group of patients after surgery. Reporting by Anadolu Agency also noted that longer follow-up is needed to determine whether this translates into longer overall survival. According to information published by the cancer center on October 23, the vaccine had not yet been approved by the U.S. Food and Drug Administration at that time. The phase 3 results add clinical evidence for personalized cancer treatment, but regulatory review and practical supply remain hurdles before it can become a routine option.

References

  1. Anadolu Agency
  2. Moderna
  3. Memorial Sloan Kettering Cancer Center